InsiderTrades

Form 4 for HAE HAEMONETICS CORP

Accepted 2024-05-21 00:00:00 ET · period of report 2024-05-17 · accession 0001127602-24-016171 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-05-21 2024-05-17 HAE Lingamneni Anila EVP, CTO A - Grant — +3,394 14.7K +30% —
D 2024-05-21 2024-05-17 HAE Lingamneni Anila EVP, CTO F - Tax $95.73 -349 11.3K -3% -$33.4K
D 2024-05-21 2024-05-17 HAE Lingamneni Anila EVP, CTO A - Grant $0.00 +7,461 7,461 New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-05-17 A A 3,394 — 14,685 D — — (F3) The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. (F4) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. (F2) This number includes unvested RSUs previously reported.
2 Common Common Stock 2024-05-17 F D 349 $95.73 11,291 D — — (F1) Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. (F2) This number includes unvested RSUs previously reported.
3 Derivative Non-qualified Stock Option (Right to Buy) 2024-05-17 A A 7,461 $0.00 7,461 D $95.73 · — to 2031-05-17 7,461 Common Stock (F5) Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.